Which has better valuation & earnings, MANE or BBIO?

Veradermics has higher earnings, but lower revenue than BridgeBio Pharma. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A N/A N/A BridgeBio Pharma $502.08M 26.06 -$724.93M -$3.74 N/A

Is MANE or BBIO more profitable?

Veradermics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%. Company Net Margins Return on Equity Return on Assets Veradermics N/A N/A N/A BridgeBio Pharma -124.42% N/A -65.81%

Does the media refer more to MANE or BBIO?

In the previous week, BridgeBio Pharma had 13 more articles in the media than Veradermics. MarketBeat recorded 15 mentions for BridgeBio Pharma and 2 mentions for Veradermics. BridgeBio Pharma's average media sentiment score of 1.19 beat Veradermics' score of 0.54 indicating that BridgeBio Pharma is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BridgeBio Pharma 11 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger earnings and valuation, ASND or MANE?

Veradermics has lower revenue, but higher earnings than Ascendis Pharma A/S. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Ascendis Pharma A/S $814.57M 16.70 -$258M $8.67 25.15 Veradermics N/A N/A N/A N/A N/A

Is ASND or MANE more profitable?

Ascendis Pharma A/S has a net margin of 57.87% compared to Veradermics' net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Ascendis Pharma A/S 57.87% N/A -8.37% Veradermics N/A N/A N/A

Does the media prefer ASND or MANE?

In the previous week, Ascendis Pharma A/S had 10 more articles in the media than Veradermics. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 2 mentions for Veradermics. Ascendis Pharma A/S's average media sentiment score of 1.10 beat Veradermics' score of 0.54 indicating that Ascendis Pharma A/S is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Ascendis Pharma A/S 6 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has better valuation & earnings, MANE or AXSM?

Veradermics has higher earnings, but lower revenue than Axsome Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veradermics N/A N/A N/A N/A N/A Axsome Therapeutics $638.50M 20.57 -$183.17M -$3.73 N/A

Does the media favor MANE or AXSM?

In the previous week, Axsome Therapeutics had 21 more articles in the media than Veradermics. MarketBeat recorded 23 mentions for Axsome Therapeutics and 2 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 0.67 beat Veradermics' score of 0.54 indicating that Axsome Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veradermics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Axsome Therapeutics 13 Very Positive mention(s) 3 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation & earnings, ELAN or MANE?

Veradermics has lower revenue, but higher earnings than Elanco Animal Health. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Elanco Animal Health $4.72B 2.56 -$232M -$0.50 N/A Veradermics N/A N/A N/A N/A N/A

Does the media favor ELAN or MANE?

In the previous week, Elanco Animal Health had 5 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Elanco Animal Health and 2 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 1.19 beat Veradermics' score of 0.54 indicating that Elanco Animal Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Elanco Animal Health 5 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has stronger valuation & earnings, SMMT or MANE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Summit Therapeutics N/A N/A -$1.08B -$1.60 N/A Veradermics N/A N/A N/A N/A N/A

Is SMMT or MANE more profitable?

Veradermics' return on equity of 0.00% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Summit Therapeutics N/A -291.24% -243.07% Veradermics N/A N/A N/A

Does the media prefer SMMT or MANE?

In the previous week, Summit Therapeutics had 11 more articles in the media than Veradermics. MarketBeat recorded 13 mentions for Summit Therapeutics and 2 mentions for Veradermics. Summit Therapeutics' average media sentiment score of 0.84 beat Veradermics' score of 0.54 indicating that Summit Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Summit Therapeutics 4 Very Positive mention(s) 2 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Veradermics 0 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Veradermics (MANE) Competitors

$95.91 -0.16 (-0.17%)

Closing price 06/12/2026 03:59 PM Eastern

Extended Trading

$96.12 +0.21 (+0.22%)

As of 06/12/2026 06:58 PM Eastern

Compare

MANE vs. BBIO, ASND, AXSM, ELAN, and SMMT

Should you buy Veradermics stock or one of its competitors? MarketBeat compares Veradermics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Veradermics include BridgeBio Pharma (BBIO), Ascendis Pharma A/S (ASND), Axsome Therapeutics (AXSM), Elanco Animal Health (ELAN), and Summit Therapeutics (SMMT). These companies are all part of the "pharmaceutical products" industry.

How does Veradermics compare to BridgeBio Pharma?

Veradermics (NYSE:MANE) and BridgeBio Pharma (NASDAQ:BBIO) are both pharmaceutical products companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

99.9% of BridgeBio Pharma shares are held by institutional investors. 14.2% of BridgeBio Pharma shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BridgeBio Pharma had 13 more articles in the media than Veradermics. MarketBeat recorded 15 mentions for BridgeBio Pharma and 2 mentions for Veradermics. BridgeBio Pharma's average media sentiment score of 1.19 beat Veradermics' score of 0.54 indicating that BridgeBio Pharma is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BridgeBio Pharma	11 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Veradermics has higher earnings, but lower revenue than BridgeBio Pharma.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	N/A	N/A
BridgeBio Pharma	$502.08M	26.06	-$724.93M	-$3.74	N/A

Veradermics has a net margin of 0.00% compared to BridgeBio Pharma's net margin of -124.42%.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
BridgeBio Pharma	-124.42%	N/A	-65.81%

Veradermics presently has a consensus price target of $109.00, indicating a potential upside of 13.65%. BridgeBio Pharma has a consensus price target of $89.59, indicating a potential upside of 34.12%. Given BridgeBio Pharma's stronger consensus rating and higher probable upside, analysts clearly believe BridgeBio Pharma is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
BridgeBio Pharma	1 Sell rating(s)	2 Hold rating(s)	23 Buy rating(s)	0 Strong Buy rating(s)	2.85

Summary

BridgeBio Pharma beats Veradermics on 8 of the 10 factors compared between the two stocks.

How does Veradermics compare to Ascendis Pharma A/S?

Ascendis Pharma A/S (NASDAQ:ASND) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, profitability, earnings, media sentiment, analyst recommendations and risk.

Ascendis Pharma A/S currently has a consensus price target of $295.39, suggesting a potential upside of 35.46%. Veradermics has a consensus price target of $109.00, suggesting a potential upside of 13.65%. Given Ascendis Pharma A/S's stronger consensus rating and higher probable upside, equities analysts clearly believe Ascendis Pharma A/S is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ascendis Pharma A/S	1 Sell rating(s)	0 Hold rating(s)	16 Buy rating(s)	2 Strong Buy rating(s)	3.00
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Veradermics has lower revenue, but higher earnings than Ascendis Pharma A/S.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ascendis Pharma A/S	$814.57M	16.70	-$258M	$8.67	25.15
Veradermics	N/A	N/A	N/A	N/A	N/A

In the previous week, Ascendis Pharma A/S had 10 more articles in the media than Veradermics. MarketBeat recorded 12 mentions for Ascendis Pharma A/S and 2 mentions for Veradermics. Ascendis Pharma A/S's average media sentiment score of 1.10 beat Veradermics' score of 0.54 indicating that Ascendis Pharma A/S is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Ascendis Pharma A/S	6 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ascendis Pharma A/S has a net margin of 57.87% compared to Veradermics' net margin of 0.00%.

Company	Net Margins	Return on Equity	Return on Assets
Ascendis Pharma A/S	57.87%	N/A	-8.37%
Veradermics	N/A	N/A	N/A

Summary

Ascendis Pharma A/S beats Veradermics on 8 of the 9 factors compared between the two stocks.

How does Veradermics compare to Axsome Therapeutics?

Veradermics (NYSE:MANE) and Axsome Therapeutics (NASDAQ:AXSM) are both pharmaceutical products companies, but which is the better business? We will compare the two companies based on the strength of their valuation, media sentiment, dividends, analyst recommendations, risk, earnings, profitability and institutional ownership.

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Veradermics has a net margin of 0.00% compared to Axsome Therapeutics' net margin of -26.59%. Veradermics' return on equity of 0.00% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veradermics	N/A	N/A	N/A
Axsome Therapeutics	-26.59%	-267.16%	-28.53%

Veradermics has higher earnings, but lower revenue than Axsome Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veradermics	N/A	N/A	N/A	N/A	N/A
Axsome Therapeutics	$638.50M	20.57	-$183.17M	-$3.73	N/A

Veradermics currently has a consensus target price of $109.00, indicating a potential upside of 13.65%. Axsome Therapeutics has a consensus target price of $256.79, indicating a potential upside of 0.63%. Given Veradermics' higher probable upside, equities analysts plainly believe Veradermics is more favorable than Axsome Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Axsome Therapeutics	1 Sell rating(s)	0 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	2.95

In the previous week, Axsome Therapeutics had 21 more articles in the media than Veradermics. MarketBeat recorded 23 mentions for Axsome Therapeutics and 2 mentions for Veradermics. Axsome Therapeutics' average media sentiment score of 0.67 beat Veradermics' score of 0.54 indicating that Axsome Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veradermics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Axsome Therapeutics	13 Very Positive mention(s)	3 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats Veradermics on 8 of the 12 factors compared between the two stocks.

How does Veradermics compare to Elanco Animal Health?

Elanco Animal Health (NYSE:ELAN) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the better stock? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, risk, dividends, profitability, media sentiment and analyst recommendations.

Elanco Animal Health presently has a consensus price target of $28.20, suggesting a potential upside of 16.56%. Veradermics has a consensus price target of $109.00, suggesting a potential upside of 13.65%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, analysts plainly believe Elanco Animal Health is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Elanco Animal Health	1 Sell rating(s)	2 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.77
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Veradermics has lower revenue, but higher earnings than Elanco Animal Health.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Elanco Animal Health	$4.72B	2.56	-$232M	-$0.50	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

Veradermics has a net margin of 0.00% compared to Elanco Animal Health's net margin of -4.95%. Elanco Animal Health's return on equity of 7.42% beat Veradermics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Elanco Animal Health	-4.95%	7.42%	3.66%
Veradermics	N/A	N/A	N/A

97.5% of Elanco Animal Health shares are owned by institutional investors. 1.1% of Elanco Animal Health shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

In the previous week, Elanco Animal Health had 5 more articles in the media than Veradermics. MarketBeat recorded 7 mentions for Elanco Animal Health and 2 mentions for Veradermics. Elanco Animal Health's average media sentiment score of 1.19 beat Veradermics' score of 0.54 indicating that Elanco Animal Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Elanco Animal Health	5 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Elanco Animal Health beats Veradermics on 11 of the 12 factors compared between the two stocks.

How does Veradermics compare to Summit Therapeutics?

Summit Therapeutics (NASDAQ:SMMT) and Veradermics (NYSE:MANE) are both pharmaceutical products companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, profitability, dividends, risk, earnings, institutional ownership, analyst recommendations and valuation.

In the previous week, Summit Therapeutics had 11 more articles in the media than Veradermics. MarketBeat recorded 13 mentions for Summit Therapeutics and 2 mentions for Veradermics. Summit Therapeutics' average media sentiment score of 0.84 beat Veradermics' score of 0.54 indicating that Summit Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Summit Therapeutics	4 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Veradermics	0 Very Positive mention(s)	2 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summit Therapeutics currently has a consensus target price of $27.23, indicating a potential upside of 94.33%. Veradermics has a consensus target price of $109.00, indicating a potential upside of 13.65%. Given Summit Therapeutics' higher probable upside, equities research analysts clearly believe Summit Therapeutics is more favorable than Veradermics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Summit Therapeutics	2 Sell rating(s)	6 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.47
Veradermics	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.60	N/A
Veradermics	N/A	N/A	N/A	N/A	N/A

Veradermics' return on equity of 0.00% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Summit Therapeutics	N/A	-291.24%	-243.07%
Veradermics	N/A	N/A	N/A

4.6% of Summit Therapeutics shares are owned by institutional investors. 83.5% of Summit Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Summit Therapeutics beats Veradermics on 7 of the 10 factors compared between the two stocks.

Get Veradermics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MANE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

MANE vs. The Competition

Export

Metric	Veradermics	Pharmaceutical Preparations Industry	Manufacturing Sector	NYSE Exchange
Market Cap	$4.01B	$979.54M	$4.29B	$23.31B
Dividend Yield	N/A	4.84%	10.25%	4.05%
P/E Ratio	N/A	1.45	22.29	31.31
Price / Sales	N/A	120.49	159.54	100.04
Price / Cash	N/A	20.06	40.19	18.65
Price / Book	N/A	7.85	26.92	4.69
Net Income	N/A	-$4.88M	$116.61M	$1.08B
7 Day Performance	5.70%	0.64%	0.25%	2.07%
1 Month Performance	-3.88%	-0.16%	0.25%	3.44%
1 Year Performance	N/A	47.51%	14.25%	24.11%

Veradermics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
MANE Veradermics	N/A	$95.91 -0.2%	$109.00 +13.6%	N/A	$4.01B	N/A	N/A	19	Analyst Upgrade Gap Up
BBIO BridgeBio Pharma	3.6889 of 5 stars	$67.61 flat	$89.59 +32.5%	+67.9%	$13.24B	$502.08M	N/A	400	Positive News
ASND Ascendis Pharma A/S	4.549 of 5 stars	$210.45 flat	$295.39 +40.4%	+27.7%	$13.13B	$865.78M	24.27	1,189	Positive News
AXSM Axsome Therapeutics	1.6771 of 5 stars	$232.32 flat	$251.26 +8.2%	+145.1%	$11.96B	$708.24M	N/A	380
ELAN Elanco Animal Health	3.5723 of 5 stars	$23.61 -0.1%	$28.20 +19.4%	+75.1%	$11.79B	$4.72B	N/A	9,400	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NYSE:MANE) was last updated on 6/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Veradermics (MANE) Competitors

MANE vs. BBIO, ASND, AXSM, ELAN, and SMMT

How does Veradermics compare to BridgeBio Pharma?

Summary

How does Veradermics compare to Ascendis Pharma A/S?

Summary

How does Veradermics compare to Axsome Therapeutics?

Summary

How does Veradermics compare to Elanco Animal Health?

Summary

How does Veradermics compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Veradermics (MANE) Competitors

MANE vs. BBIO, ASND, AXSM, ELAN, and SMMT

How does Veradermics compare to BridgeBio Pharma?

Do institutionals and insiders believe in MANE or BBIO?

Does the media refer more to MANE or BBIO?

Which has better valuation & earnings, MANE or BBIO?

Is MANE or BBIO more profitable?

Do analysts rate MANE or BBIO?

Summary

How does Veradermics compare to Ascendis Pharma A/S?

Do analysts prefer ASND or MANE?

Which has stronger earnings and valuation, ASND or MANE?

Does the media prefer ASND or MANE?

Is ASND or MANE more profitable?

Summary

How does Veradermics compare to Axsome Therapeutics?

Do institutionals & insiders hold more shares of MANE or AXSM?

Is MANE or AXSM more profitable?

Which has better valuation & earnings, MANE or AXSM?

Do analysts rate MANE or AXSM?

Does the media favor MANE or AXSM?

Summary

How does Veradermics compare to Elanco Animal Health?

Do analysts prefer ELAN or MANE?

Which has higher valuation & earnings, ELAN or MANE?

Is ELAN or MANE more profitable?

Do institutionals and insiders have more ownership in ELAN or MANE?

Does the media favor ELAN or MANE?

Summary

How does Veradermics compare to Summit Therapeutics?

Does the media prefer SMMT or MANE?

Do analysts recommend SMMT or MANE?

Which has stronger valuation & earnings, SMMT or MANE?

Is SMMT or MANE more profitable?

Do institutionals and insiders have more ownership in SMMT or MANE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

MANE vs. The Competition

Veradermics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools